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Abstract
Postprandial hyperglycemia is characterized by hyperglycemic spikes that induce endothelial
dysfunction, inflammatory reactions and oxidative stress, which may lead to progression of
atherosclerosis and occurrence of cardiovascular events. Emerging data indicate that postprandial
hyperglycemia or even impaired glucose tolerance may predispose to progression of
atherosclerosis and cardiovascular events. There is evidence that postprandial hyperglycemia, but
not fasting hyperglycemia, independently predicts the occurrence of cardiovascular events. We
proposed a concept of 'vascular failure' as a comprehensive syndrome of vascular dysfunction
extending from risk factors to advanced atherosclerotic disease. Postprandial hyperglycemia is
therefore one of the very important pathophysiological states contributing to vascular failure.
Accordingly, controlling postprandial hyperglycemia should be the focus of future clinical
investigation as a potential target for preventing vascular failure.
Introduction
Type 2 diabetes is associated with a markedly increased
risk for atherosclerotic coronary arteries and cerebrovascu-
lar diseases [1,2]. In addition, there is evidence that
abnormalities during the postprandial state, specifically
postprandial hyperglycemia, are independent risk factors
for atherosclerosis [3]. Recent epidemiological studies
suggest postprandial hyperglycemia is an independent
risk factor for cardiovascular disease that has effects
greater than that of fasting hyperglycemia [4-6].
Atherosclerosis is a progressive disease characterized by
the response of the vessel wall to chronic, multifactorial
injury, which leads ultimately to the formation of athero-
matous or fibrous plaques. Endothelial dysfunction is
thought to be the initial stage of atherosclerosis. In addi-
tion to endothelial dysfunction, smooth muscle cell dys-
function metabolic abnormalities of the vessel wall
including inflammation, oxidative stress and breakdown
of neurohormonal balance occur in the early stage of the
atherosclerosis process. We recently proposed a new con-
cept termed 'vascular failure' that represents an integra-
tion of these vascular abnormalities [7]. Although
Schwartz et al. formerly used the term 'vascular failure' as
the failure of vascular remodeling response [8], our 'vas-
cular failure' is distinguished from theirs and is defined as
a comprehensive syndrome of vascular dysfunction
extending from risk factors to advanced atherosclerotic
disease with arterial stenosis, and finally to calcification of
the vessel wall or serious vascular events caused by plaque
rupture or thromboembolic occlusion (Fig. 1),
The pathophysiology of postprandial hyperglycemia is
characterized by hyperglycemic spikes that induce oxida-
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tive stress [9], which in combination with soluble
advanced glycation end products (AGEs) and lipid perox-
idation products, act as key activators of upstream kinases,
leading to endothelial dysfunction and expression of
inflammatory genes [10] (Fig. 2). This article is an over-
view of the role of postprandial hyperglycemia, as a major
fundamental disturbance, in the pathogenesis of vascular
failure.
Recent evidence suggests that almost 2 of 3 patients with
symptomatic cardiovascular disease have abnormal glu-
cose homeostasis [11]. A significant number of these
patients are not detected by increased fasting glucose lev-
els, but rather by the presence of elevated glucose levels
following a meal or during an oral glucose tolerance test
[12]. Glucose intolerance is generally established by a 75
g glucose load test, with impaired glucose tolerance, or
prediabetes, defined as a 2-hour postload glucose level of
140 to 200 mg/dl and overt type 2 diabetes as a postload
glucose level>200 mg/dl. Postprandial hyperglycemia
often occurs, even in the setting of good diabetic control
assessed by hemoglobin A1c (HbA1c) and fasting glucose
levels [13]. Population studies have shown that a fasting
glucose level as low as 90 mg/dl may be associated with a
2-hour postprandial glucose level >200 mg/dl [14,15]. In
the early stages of type 2 diabetes, even when fasting glu-
cose and HbA1c are within nornal ranges, postprandial
hyperglycemia causes macrovascular complications such
as myocardial infarction or stroke as well as microvascular
complications [12,14,16,17]. Emerging data indicate that
even impaired glucose tolerance may predispose to pro-
gression of atherosclerosis and cardiovascular events [12].
There is evidence that postprandial hyperglycemia, but
not fasting hyperglycemia, independently predicts the
occurrence of cardiovascular events [16]. For example, the
Funagata Diabetes Study showed consistently that 1- or 2-
hour postload glucose levels were better predictors of car-
diovascular risk than either fasting glucose or HbA1c lev-
els [14], while the Diabetic Epidemiology: Collaborative
Analysis of Diagnosis Criteria in Europe (DECODE) study
demonstrated a continuous graded and direct relation-
ship between 2-hour postload glucose levels and risk for
cardiovascular death [18]. Even in patients classified as
having normal glucose tolerance with a postload glucose
<140 mg/dl, the level of postload glycemia correlates with
the risk of cardiovascular death and all-cause mortality
[19]. The risk for postload glycemia begins to increase at
levels >80 mg/dl and by 140 mg/dl, the point at which
patients are traditionally classified as having impaired glu-
cose tolerance (IGT) or prediabetes, cardiovascular risk is
already increased by 58%.
It is now well recognized that endothelial dysfunction is
the initial stage in the development of atherosclerosis
[20]. Endothelial dysfunction is characterized by a reduc-
tion in the production and bioavailability of endothe-
lium-derived relaxing factors, in particular, nitric oxide
(NO), generated from L-arginine by endothelial NO syn-
thase (eNOS). A reduction in NO bioavailability leads to
impaired endothelium-dependent vasodilation, the func-
tional manifestation of endothelial dysfunction [21]. On
the other hand, it also comprises a specific state of
"endothelial activation", characterized by a proinflamma-
tory, proliferative and procoagulation milieu that
Vasculular failure Figure 1
Vasculular failure. Vascular failure represents a compre-
hensive syndrome of vascular dysfunction that extends from 
risk factors to advanced atherosclerotic disease with arterial 
stenosis, leading ultimately to calcification of the vessel wall 
and serious vascular events caused by plaque rupture and 
thromboembolic occlusion. Calcification includes medial cal-
cification, e.g., in aortic wall as result of diabetes and intimal 
calcification, e.g., in coronary artery.
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Pathophysiology of postprandial hyperglycemia Figure 2
Pathophysiology of postprandial hyperglycemia. 
Hyperglycemic spikes following every meal induce oxidative 
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enhances all the various stages of atherogenesis [22].
Given this relationship between endothelial dysfunction
and atherosclerosis, it is likely that the status of endothe-
lial function may reflect the propensity of an individual to
develop atherosclerotic disease. The presence of endothe-
lial dysfunction therefore serves as an early marker of vas-
cular failure.
Endothelial function is impaired not only in patients with
diabetes but also in patients with IGT. We observed flow-
mediated vasodilation (FMD) was reduced in patients
with IGT, compared to subjects with normal glucose tol-
erance (Fig. 3). An acute increase in glycemia affects
endothelial function, with both in vitro and in vivo studies
confirming this direct role of hyperglycemia. The presence
of high glucose concentrations in vitro reduces acetylcho-
line-induced endothelium-dependent vasodilation in a
concentration-dependent manner, with the effect being
obtained simply by exposing the preparations to high glu-
cose levels [23]. In vivo studies have also demonstrated
that hyperglycemic spikes induce endothelial dysfunction
[24,25]. Williams et al. [26], using FMD, showed that
acute hyperglycemia induced in healthy subjects by intra-
arterial infusion of 50% dextrose resulted in impaired
endothelium-dependent vasodilation. This finding indi-
cates that elevated glucose levels are a major cause of
endothelial dysfunction associated with diabetes mellitus.
Shige et al. [27] also demonstrated FMD was attenuated
after the intake of fat- and sucrose-rich meals in patients
with type 2 diabetes. They showed both the level and
change in postprandial FMD correlated significantly with
postprandial changes in blood glucose levels, thereby
establishing postprandial hyperglycemia as a determinant
of reduced flow-mediated vasodilation.
These effects of hyperglycemia are probably linked with
reduced production and/or bioavailability of NO, as
hyperglycemia-induced endothelial dysfunction is coun-
terbalanced by increased production of arginine [28]. The
inter-relationship between NO production and bioavaila-
bility has to be fully understood, because it is not yet clear
whether hyperglycemia reduces production of NO, or
more probably, increases NO production in association
with significant increases in the levels of its inhibitor, the
superoxide anion, resulting in a reduction in NO bioavail-
ability [29]. Furthermore, a rapid decrease in FMD has
been demonstrated in patients with IGT during an OGTT
that correlated with the degree of glycemia measured at 2
hours [25].
Recent data suggest that AGEs also have a role in the devel-
opment of endothelial dysfunction [30]. AGEs are a heter-
ogeneous group of moieties, one of the most
representative being carboxymethyllysine (CML). Diet is a
major source of exogenous AGEs, with food AGE content
being highly dependent on food nutrient composition, as
well as the method, temperature and duration of cooking
[31]. Approximately 10% of ingested AGEs are absorbed
rapidly and partly retained in the body, where they exert a
variety of pathological effects [32] including binding and
activation of AGE receptors [33]. AGE precursors such as
methylglyoxal (MG) also activate AGE receptors, with an
in vivo study demonstrating endogenous MG synthesis
increased in parallel with hyperglycemia [34]. In the post-
prandial period, absorbed and endogenously generated
AGEs and MG act synergistically to decrease vascular func-
tion by directly scavenging NO and increasing oxidative
stress.
Inflammation in postprandial hyperglycemia
It is well established that inflammation is a major factor
in the pathogenesis of vascular failure. Inflammation in
diabetes has long been assessed and considered by the
measurement of various inflammatory markers such as
high-sensitivity C reactive protein (hsCRP). Various
inflammatory cells and mediators play an essential role in
the inflammatory process, with initiation and progression
of atherosclerosis being characterized by recruitment of
leukocytes such as monocytes and T-lymphocytes to the
endothelium of the artery wall. Adhesion molecules regu-
late this interaction between the endothelium and leuko-
cytes [35]. Of the various adhesion molecules,
intracellular adhesion molecule (ICAM)-1 and vascular
cell adhesion molecule (VCAM)-1 have attracted particu-
lar interest. An increase in the circulating forms of these
molecules has been demonstrated in subjects with vascu-
lar disease [36] and also in subjects with diabetes, with or
without vascular disease [37,38]. We observed that circu-
lating levels of ICAM-1, but not VCAM-1, were higher
even in patients with IGT, compared to healthy subjects
Markers of endothelial function and inflammation in patients  with impaired glucose tolerance and subjects with normal  glucose tolerance (control) Figure 3
Markers of endothelial function and inflammation in 
patients with impaired glucose tolerance and sub-
jects with normal glucose tolerance (control). Com-
pared to control subjects, patients with IGT have reduced 
flow mediated vasodilation and higher circulating levels of 
ICAM-1, but not VCAM-1.Cardiovascular Diabetology 2009, 8:23 http://www.cardiab.com/content/8/1/23
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(Fig. 3). In addition, it has been demonstrated that acute
hyperglycemia in both normal and diabetic subjects is a
sufficient stimulus to increase circulating levels of ICAM-
1, thereby activating one of the first stages of the athero-
genic process [39,40]. The concept of atherosclerosis as an
inflammatory disease, even in diabetes, is now well estab-
lished [41], with evidence that acute hyperglycemia dur-
ing either a hyperglycemic clamp [42] or the postprandial
state [43] increases production of plasma interleukin-6,
tumor necrosis factor-α and interleukin-18.
Although previous research has focused on monocytes
and T-lymphocytes as the predominant types of inflam-
matory cells involved in atherosclerosis [44,45], there is
growing evidence that neutrophil activation is also a
major participant in the inflammatory process of ischemic
cardiovascular disease, particularly during the acute
inflammatory response. In addition, of the various types
of leukocytes, the neutrophil count was shown to be the
best predictor of future cardiovascular events in a large
patient cohort with a high risk of coronary artery and cer-
ebrovascular diseases [45]. Peripheral neutrophils are the
most important productive source of reactive oxygen spec-
imens. Activated neutrophils contribute markedly to oxi-
dative stress and inflammation in type 2 diabetes, which
subsequently evolves causing angiopathy and atheroscle-
rosis [46]. An adhesion molecule, β2-integrin Mac-1
(CD11b/CD18), is essential for firm adhesion of both
neutrophils and monocytes to vascular endothelial cells.
Mac-1 binds to endothelial surface ICAM-1 [47] and also
to platelets by binding to either fibrinogen or several
platelet receptors such as glycoprotein (GP) Ibα [48] and
ICAM-2 [49]. Clinical studies have shown that Mac-1 is
activated and upregulated on the surface of neutrophils
localized in injured vessels following coronary angi-
oplasty [50]. Upregulation of Mac-1 on the surface of neu-
trophils has also been observed in patients with type 2
diabetes [51]. In addition, it has been reported that ago-
nist-induced ex-vivo upregulation of Mac-1 on the surface
of neutrophils is enhanced in patients with diabetes [52].
We have previously observed expression of Mac-1 on the
surface of isolated neutrophils using flowcytometric anal-
ysis before and 120 min after an oral 75 g glucose load in
patients who had not been diagnosed with diabetes mel-
litus and whose fasting plasma glucose level was <126
mg/dl. Our results showed that compared to baseline val-
ues, Mac-1 was upregulated even on unstimulated neu-
trophils 120 min after the glucose load in patients with
postprandial hyperglycemia, defined as a glucose level of
≥ 200 mg/dl at 120 min. In addition, upregulation of
fMLP-induced Mac-1 was enhanced significantly at 120
min compared to baseline, not only in patients with post-
prandial hyperglycemia, but also in patients with IGT
defined as a glucose level at 120 mim ≥ 140 mg/dl. How-
ever, these changes were not evident in patients with nor-
mal glucose tolerance defined as a glucose level <140 mg/
dl at 120 min (Fig. 3). These results suggest that acute
increases in plasma glucose may alter neutrophil function
from inactivated to potentially activated forms in patients
with postprandial hyperglycemia and impaired glucose
tolerance.
Contribution of postprandial hyperglycemia to 
oxidative stress
Oxidative stress defined as dysregulation of the cellular
redox state, plays a pivotal role in the pathogenesis of vas-
cular failure, especially vascular endothelial dysfunction
[53]. The superoxide anion is formed by univalent reduc-
tion of molecular oxygen. Although several enzymes are
involved in the generation of superoxide anions, includ-
ing xanthine oxidase, NADH/NADPH oxidase, lipoxygen-
ase and NOS, mitochondria are the major source of
superoxide anion production in vivo [54]. Superoxide ani-
ons are reduced to hydrogen peroxide either spontane-
ously or by enzymatic catalyzed dismutation. Transition
metal- catalyzed interactions between iron or copper and
hydrogen peroxide produce highly toxic hydroxyl radi-
cals. Recent studies demonstrate that hyperglycemia
induces an overproduction of superoxide anions by the
mitochondrial electron-transport chain [55]. Superoxide
overproduction is accompanied by increased NO produc-
tion, caused by an uncoupled state between eNOS and
inducible NOS (iNOS), a phenomenon that favors the
formation of the strong oxidant, peroxynitrite, which in
turn damages DNA. DNA damage is an obligatory stimu-
lus for activation of the nuclear enzyme poly(ADP-ribose)
polymerase. Poly(ADP-ribose) polymerase activation, in
turn, depletes the intracellular concentration of its sub-
strate NAD+, resulting in a decreased rate of glycolysis,
electron transport and adenosine triphosphate formation,
leading to adenosine diphospate-ribosylation of reduced
glyceraldehyde-phosphate dehydrogenase [56]. These
processes result in acute endothelial dysfunction in dia-
betic blood vessels that contributes overtly to the develop-
ment of cardiovascular disease. There is both indirect and
direct evidence to support the concept that acute hyperg-
lycemia promotes the development of cardiovascular dis-
ease in subjects with IGT through the production of
oxidative stress. The direct evidence is based on the effects
of postprandial hyperglycemia on oxidative stress markers
such as nitrotyrosine and 8-iso-prostaglandin F2α (8-iso-
PGF2α).
Oxygen free radicals react with nitric oxide to form perox-
ynitrite, a powerful oxidant that may directly oxidize pro-
teins, lipids, and DNA through a nitronium-like
intermediate, resulting in formation of carbonyls from
side-chain and peptide-bond cleavage [57]. Peroxynitrite
has an affinity for tyrosine residues, with this reaction pro-
ducing nitrotyrosine [58]. Evidence from several studiesCardiovascular Diabetology 2009, 8:23 http://www.cardiab.com/content/8/1/23
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supports a direct role of hyperglycemia promoting over-
generation of nitrotyrosine. For example, nitrotyrosine
formation has been detected in the artery walls of mon-
keys during hyperglycemia [59], in the plasma of healthy
subjects during hyperglycemic clamps [60] or OGTTs [61]
and also in patients with diabetes mellitus during an
increase in postprandial hyperglycemia, with nitrotyro-
sine production being dependent on the level of glycemia
[62]. Hyperglycemia was also observed to be accompa-
nied by nitrotyrosine deposition in perfused working
hearts of rats, that appeared to be related to unbalanced
production of NO and superoxide anion caused by over-
expression of iNOS [63]. Nitrotyrosine formation has
been shown to be followed by the development of
endothelial dysfunction in both healthy subjects [60] and
in the coronary arteries of perfused hearts [63]. This effect
is not surprising, as nitrotyrosine has been shown to be
directly harmful to endothelial cells [64].
Determination of specific isoprostane isomers such as 8-
iso-PGF2α in urine have been proposed as markers of oxi-
dative stress. Isoprostane is formed collectively from free
radical-mediated oxidation of arachidonic acid [65]. As
this fatty acid is distributed ubiquitously in cell mem-
branes, measurement of urinary isoprostanes most likely
provides an excellent reflection of oxidative stress in the
whole body. Several studies have demonstrated hypergly-
cemia is associated with increased rate of formation and
urinary excretion rate of 8-iso-PGF2α [66]. The urinary
excretion rate of 8-iso-PGF2α has been reported to be
increased significantly in patients with type 2 diabetes
patients compared with age-matched healthy subjects.
Furthermore, a significant correlation was observed
between blood glucose and urinary 8-iso-PGF2α, suggest-
ing that an increase in oxidative stress may be related, at
least in part, to determinants of diabetic control. Such
results are consistent with in vitro findings of enhanced
formation and release of 8-iso-PGF2α by porcine vascular
smooth muscle cells cultured under hyperglycemic condi-
tions [67]. In a recent study, Monnier et al. [68] demon-
strated a strong positive correlation between the urinary
excretion rate of 8-iso-PGF2α  and glycemic variability
assessed by the mean amplitude of glycemic excursions
(MAGE). A statistically significant correlation was also
observed with the mean postprandial glucose increment,
although this relationship was not as strong. These find-
ings indicate that the triggering effect of acute glycemic
excursions on oxidative stress should be integrated into
glycemic disorders as they are much broader than acute
postprandial spikes. As a consequence, the concept that
postprandial hyperglycemic spikes are "dangerous waves"
should be extended to both upward (postprandial) and
downward (interprandial) acute fluctuations of glucose
levels around a mean value.
Therapeutic Paradigm
A number of clinical trials have demonstrated that specific
pharmacological approaches can reduce the impact of
postprandial glycemic excursions on overall glycemic con-
trol [69-71]. However, to date, there have been no pro-
spective clinical trials evaluating the impact of improved
postprandial hyperglycemia on long-term outcomes in
patients with diabetes. Given recent data on the impact of
postprandial glycemia on overall glucose control [72], it is
likely that therapeutic approaches that focus on this
aspect of overall glycemia will benefit patients in the long
term. Traditional diabetic agents such as insulin and sul-
fonylureas predominantly lower fasting glucose and are
less effective at reducing postprandial hyperglycemia.
Although sulfonylureas target insulin secretion directly
through the beta cell potassium channel, they may also
have an impact on fasting and postprandial glycemia.
However, the pharmacokinetics of the majority of these
agents are not tailored toward acute insulin release, and
therefore they do not correct abnormalities in early-phase
insulin secretion [73]. On the other hand, the pharmacok-
inetics and mechanisms of action of several agents are
directed specifically at postprandial hyperglycemia. Such
agents include the meglitinide class of drugs, α-glucosi-
dase inhibitors and thiazolidinediones.
The meglitinide analogues include repaglinide, nategli-
nide and mitiglinide, which are modern nonsulfonylurea
secretagogues that restore the first-phase insulin response.
A single dose of nateglinide has been shown to reduce
postprandial endothelial dysfunction by lowering post-
load glycemia in patients with type 2 diabetes [74]. In a
randomized trial of diabetic patients, repaglinide reduced
postprandial glucose levels to a greater degree than the
sulfonylurea, glyburide, whereas glyburide was more
effective for lowering fasting glucose levels. Despite iden-
tical reductions in HbA1c levels in the 2 groups, repagli-
nide caused regression of carotid intima-media thickness
in 52% of patients, compared with only 18% of patients
treated with glyburide [75]. This regression in atheroscle-
rosis was shown to be directly proportional to the reduc-
tion in postprandial hyperglycemia.
Alpha-glucosidase inhibitors block the α-glucosidase
enzyme, thereby slowing the rate of carbohydrate diges-
tion including starches and disaccharides. In diabetic or
glucose-intolerant patients, α-glucosidase inhibitors
lower postload glucose peaks by between 30 to 70 mg/dl
and reduce HbA1c by about 0.7%, with negligible effects
on fasting glucose levels [76]. Long-term acarbose therapy
also reduces the levels of triglycerides and chylomicrons,
possibly by improving insulin sensitivity [77]. A recent
study showed that even a single mixed meal of 450 calo-
ries caused substantial and immediate deterioration inCardiovascular Diabetology 2009, 8:23 http://www.cardiab.com/content/8/1/23
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endothelial function in diet-treated patients with diabetes
[76]. Pretreatment of these same subjects with a single
dose of acarbose markedly reduced postprandial hyperg-
lycemia and associated endothelial dysfunction after the
ensuing meal. The Study to Prevent Non-Insulin-Depend-
ent Diabetes Mellitus (STOP-NIDDM) was an interna-
tional trial of 1,429 subjects with impaired glucose
tolerance who were randomized to either acarbose 100
mg, 3 times daily with meals or placebo [78]. After 3.3
years, acarbose significantly reduced the primary end
point of the study, the progression to new diabetes, by
25%. In this trial, acarbose treatment was associated with
significant reductions of 49% for any cardiovascular event
and 91% for myocardial infarction. Acarbose also slowed
progression of carotid atherosclerosis and reduced the
development of new hypertension by 34%, results that
indicated postprandial dysmetabolism may play a role in
the genesis of hypertension. A large retrospective meta-
analysis of seven long-term studies of acarbose in patients
with type 2 diabetes showed significant risk reductions of
35% for cardiac events and 64% for myocardial infarction
[79]. We have also previously observed increases in FMD
and a reduction in hsCRP and VCAM-1 levels after 3
months of treatment with acarbose (Fig. 4). This suggests
attenuation of postprandial dysmetabolism induced by
acarbose results in improved endothelial function and
inflammatory status, possibly slowing the progression of
atherosclerosis. In addition, in a recent study in patients
with mild diabetes mellitus we used meal tolerance test-
ing to compare the effects of a new α-glucosidase inhibi-
tor, miglitol, with those of a meglitinide analogue,
mitiglinide, on postprandial glucose and insulin metabo-
lism. Other glucose metabolism-related markers, athero-
sclerosis-related markers and renal function were also
assessed. We showed that three months of administration
of both agents caused similar improvements in postpran-
dial hyperglycemia, although different postprandial pat-
terns of insulin secretion were observed (Fig. 5A). The
changes in 1, 5-anhydroglucitol levels after 3 months were
significantly higher in the miglitol group than in the mit-
iglinide group. Insulin resistance assessed by the homeos-
tasis model assessment index and urinary albumin
excretion decreased significantly in the miglitol group but
not in the mitiglinide group. Serum cystatin C levels did
not change in the miglitol group, although the levels
increased in the mitiglinide group. Miglitol caused a sig-
nificant decrease in hsCRP levels, whereas mitiglinide did
not (Fig. 5B and Fig 6), while serum adiponectin levels
were increased significantly only by miglitol therapy
[80,81]. These results suggest that miglitol has anti-
inflammatory and renoprotective effects, possibly associ-
ated with an improvement in insulin resistance.
Effects of acarbose on vascular endothelial function and  inflammatory status in patients with mild diabetes mellitus Figure 5
Effects of acarbose on vascular endothelial function 
and inflammatory status in patients with mild diabe-
tes mellitus. We compared flow mediated vasodilation 
(FMD) and levels of high sensitivity C reactive protein 
(hsCRP) and circulating vascular cell adhesion molecule 
(VCAM)-1 in 16 patients undergoing dietary therapy alone 
(controls) and 19 patients receiving acarbose 100 mg 3 times 
daily before each meal. FMD increased and hsCRP and 
VCAM-1 levels decreased after 3 months of acarbose treat-
ment, although these effects were absent in the controls.
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Expression of β2 integrin Mac-1 on the surface of isolated  neutrophils before and 120 min after an oral 75 g glucose  load in 11 patients with postprandial hyperglycemia (fasting  plasma glucose level <126 mg/dl and glucose level at 120 min  ≥ 200 mg/dl), 9 patients with impaired glucose tolerance  (IGT) (fasting plasma glucose level <126 mg/dl and glucose  level at 120 min ≥ 140 mg/dl) and 12 patients with normal  glucose tolerance (fasting plasma glucose level <126 mg/dl  and glucose level at 120 min <140 mg/dl) Figure 4
Expression of β2 integrin Mac-1 on the surface of iso-
lated neutrophils before and 120 min after an oral 75 
g glucose load in 11 patients with postprandial hyper-
glycemia (fasting plasma glucose level <126 mg/dl 
and glucose level at 120 min ≥ 200 mg/dl), 9 patients 
with impaired glucose tolerance (IGT) (fasting 
plasma glucose level <126 mg/dl and glucose level at 
120 min ≥ 140 mg/dl) and 12 patients with normal 
glucose tolerance (fasting plasma glucose level <126 
mg/dl and glucose level at 120 min <140 mg/dl). In 
patients with postprandial hyperglycemia, Mac-1 expression 
on unstimulated neutrophils was upregulated at 120 min after 
glucose loading compared to baseline. In addition, fMLP-
induced upregulation of Mac-1 was enhanced significantly at 
120 min in both patients with postprandial hyperglycemia and 
patients with IGT. In contrast, these changes were not evi-
dent in patients with normal glucose tolerance.
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Comparison of the effects of miglitol and mitiglinide on postprandial glucose and insulin metabolism after meal tolerance testing  in patients with mild diabetes mellitus Figure 6
Comparison of the effects of miglitol and mitiglinide on postprandial glucose and insulin metabolism after 
meal tolerance testing in patients with mild diabetes mellitus. A pre-specified breakfast was prepared, containing 63.8 
g of carbohydrate, 24.6 g of protein, 11.0 g of fat, 1.2 g of sodium and a total of 466 calories. Three months of administration of 
both agents caused similar improvements in postprandial hyperglycemia, although different patterns of insulin secretion were 
observed (A). Serum cystatin C levels did not change in the miglitol group, although the levels increased in the mitiglinide 
group. Miglitol caused a significant decrease in hsCRP levels whereas mitiglinide did not (B).
A
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The thiazolidinedione peroxisome proliferator-activated
receptor-γ (PPAR-γ) activating class of drugs, such as trogl-
itazone, rosiglitazone or pioglitazone, are insulin-sensitiz-
ing agents and are not generally considered for their
effects on insulin secretion [82]. However, as demon-
strated with troglitazone, this class of compounds, when
used in subjects with impaired glucose tolerance, may
improve glucose-coupled insulin secretion and reduce the
level of postprandial hyperglycemia [83]. PPAR-γ agonism
has been shown to have anti-inflammatory effects and to
improve endothelial function by regulating the cellular
redox state. Thiazolidinediones have also been shown to
decrease inflammatory markers such as hsCRP [84] and to
improve FMD of the brachial artery [85]. In a large rand-
omized clinical trial of pioglitazone in 5238 patients with
type 2 diabetes with macrovascular disease there was
some evidence of a reduction in adverse cardiovascular
outcomes compared to matching placebo, when the treat-
ments were taken in combination with glucose-lowering
drugs and other medications [86]. Pioglitazone was also
reported to reduce the rate of progression of carotid inti-
mal medial thickness [87] and coronary atherosclerosis
assessed by intravascular ultrasound imaging [88], when
compared to glimepiride.
Several new drugs with glucose-lowering actions that may
offer certain clinical advantages have recently become
available. These include injectable glucagon-like peptide-
1 (GLP-1) receptor agonists and oral dipeptidyl peptidase-
4 (DPP-4) inhibitors. GLP-1 receptor agonists, such as
exenatide, stimulate nutrient-induced insulin secretion
and reduce inappropriate glucagon secretion, whilst
delaying gastric emptying and reducing appetite. These
agents have a low risk of hypoglycaemia in combination
with sustained weight loss. The DPP-4 inhibitors, sitaglip-
tin and vildagliptin, are generally weight neutral, and have
less marked gastrointestinal adverse effects than the GLP-
1 receptor agonists. Vildagliptin is generally well tolerated
whether administered alone or in combination with gly-
buride or pioglitazone, and is not associated with
hypoglycemia. Co-administration of vildagliptin with
either glyburide or pioglitazone in patients with type 2
diabetes improves postprandial glycemic control without
notable effects on drug pharmacokinetics [89].
Conclusion
During postprandial hyperglycemia, hyperglycemic spikes
induce endothelial dysfunction, inflammatory reactions
and oxidative stress, which may lead to progression of
atherosclerosis and occurrence of cardiovascular events.
Epidemiological and mechanistic data suggest that post-
prandial hyperglycemia or even IGT may play a role in the
development and progression of atherosclerotic disease,
as suggested by preliminary evidence that controlling
postprandial hyperglycemia reduces the incidence of
myocardial infarction in people with IGT [78]. Postpran-
dial hyperglycemia is therefore one of the very important
pathophysiological states contributing to vascular failure.
Accordingly, controlling postprandial hyperglycemia
should be the focus of future clinical investigation as a
potential target for preventing vascular failure.
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